Kairos Pharma, Ltd. filed a preliminary proxy statement on November 20, 2026, calling a special meeting of stockholders to vote on an amendment to its 2023 Equity Incentive Plan that would increase authorized shares and modify how reverse stock splits affect the plan.

Key Highlights

  • Share pool increase: The proposed amendment would raise the maximum number of shares available for issuance under the 2023 Equity Incentive Plan to 20,000,000 shares.
  • Reverse-split carve-out: The amendment would revise Section 13 of the plan so that, upon a reverse split of outstanding common stock only, the reverse split affects only issued awards and not authorized shares.
  • Virtual-only meeting: According to the filing, the special meeting will be conducted exclusively via live audio webcast with no physical meeting location.
  • Board recommendation: The filing states the company recommends stockholders vote "FOR" both proposals on the agenda.
  • Common stock par value: Kairos Pharma common stock carries a par value of $0.001 per share, as stated in the filing.
  • Quorum requirement: A majority of the voting power of all outstanding shares entitled to vote must be represented, in person or by proxy, to constitute a quorum, the filing disclosed.

Kairos Pharma Proposes Expanded Share Pool and Reverse-Split Carve-Out for 2023 Plan

Kairos Pharma, Ltd. (NYSE:KAPA), a Delaware corporation headquartered at 2355 Westwood Blvd., #139, Los Angeles, CA 90064, submitted a preliminary proxy statement seeking stockholder approval for a single substantive proposal: an amendment to its existing 2023 Equity Incentive Plan. The filing was made on behalf of the board of directors, which is soliciting proxies for a special meeting to be held on a date noted in the filing as still to be determined.

The Plan Amendment Proposal has two components, according to the filing. First, it would increase the maximum number of shares available for issuance under the plan to 20,000,000 shares. Second, it would revise Section 13 of the plan to specify that any future reverse stock split of outstanding common stock would apply only to issued awards already granted under the plan and would not reduce the number of shares authorized for future issuance. The filing describes this as a structural clarification to the plan's mechanics in the event of a reverse split.

John S. Yu, M.D., the company's Chief Executive Officer and Chairman of the Board of Directors, signed the notice accompanying the proxy statement. The filing notes that broker non-votes will not count on Proposal 1, citing voting rules of the New York Stock Exchange, and that shares not present or represented by proxy will have no effect on the outcome of any proposal. The proxy statement and proxy card were described as being mailed to stockholders on or about a date left blank in the preliminary filing, consistent with its preliminary status.

What Was Disclosed

Kairos Pharma filed a preliminary proxy statement calling a special stockholder meeting to vote on amending its 2023 Equity Incentive Plan. The proposed changes would set the authorized share pool at 20,000,000 shares and limit the effect of any reverse stock split to already-issued awards rather than authorized shares.